COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE L'INTERLEUKINE-17 ET UN INHIBITEUR DU FACTEUR DE NÉCROSE TUMORALE ALPHA EN TANT QUE PRINCIPES ACTIFS POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE PULMONAIRE INFLAMMATOIRE NEUTROPHILIQUE
LEE, Seung Woo,이승우,KIM, Young Min,김영민,LEE, Seung Won,이승원
申请号：
KRKR2018/008879
公开号：
WO2019/124666A3
申请日:
2018.08.06
申请国别(地区):
KR
年份:
2019
代理人:
摘要：
The present invention relates to a pharmaceutical composition comprising an interleukin-17 inhibitor and a tumor necrosis factor-alpha inhibitor as effective ingredients for preventing or treating a neutrophilic lung inflammation disease or a method for screening a therapeutic material for a neutrophilic lung inflammation disease. As a result of research into a change of hematopoiesis in the bone marrow of a neutrophilic asthma mouse model in which a neutrophilic lung inflammatory response had been induced, the present inventors newly revealed G-CSF as a mediator changing the hematopoiesis of the bone marrow, furthermore identified G-CSF production induced by co-stimulation with IL-17 and TNF-α in lung epithelial cells, and experimentally investigated that the hematopoiesis of the bone marrow was normalized by administration of an anti-G-CSF antibody alone or a combination of an anti-IL-17 antibody and an anti-TNF-α antibody in the mouse model, with a resultant therapeutic effect brought about on neutrophilic asthma. Accordingly, the present invention suggests a new therapeutic target for neutrophilic lung inflammation disease, and the IL-17 inhibitor and TNF-α inhibitor according to the present invention are expected to be a new therapeutic modality for neutrophilic lung inflammation disease, which has not been effectively treated with conventional methods.La présente invention concerne une composition pharmaceutique comprenant un inhibiteur de l'interleukine-17 et un inhibiteur du facteur de nécrose tumorale alpha en tant que principes actifs pour la prévention ou le traitement d'une maladie pulmonaire inflammatoire neutrophilique, ou un procédé de recherche d'une substance thérapeutique contre une maladie pulmonaire inflammatoire neutrophilique. Suite à des recherches portant sur la modification de l'hématopoïèse dans la moelle osseuse d'un modèle de souris souffrant d'asthme neutrophilique chez lequel une réponse pulmonaire inflammatoire neutrophilique a été ind
